It will make CAR-T therapy and cellular immunotherapy research accessible to underserved communities in the greater Cleveland region and beyond. With this facility, MetroHealth becomes the first safety-net hospital in the United States to offer in-house viral vector and cellular production for a wide spectrum of medical treatments.
to offer in-house viral vector productionĬLEVELAND, Ma/PRNewswire/ - MetroHealth today announced the completion and launch of a state-of-the-art vector and cellular Good Manufacturing Practice (GMP) facility that will enable quick, reliable production and processing of the latest cutting-edge cellular immunotherapies, including chimeric antigen receptor T-cell (CAR-T) and tumor-infiltrating lymphocytes (TIL) cancer therapies. MetroHealth is the second public hospital and first safety-net hospital in the U.S.
0 kommentar(er)
